Alteogen’s ‘similarity’ for Eylea biosimilar with the original medicine
Alteogen(CEO Soon-Jae Park), an antibody biosimilar company, announced the company has secured ‘similarity’ for the Eylea biosimilar(ALT-L9) with the original medicine at a U.S. nonclinical trial and ended it without any particular adverse drug reaction.
According to Alteogen, the company has ca...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
